Context Therapeutics (NASDAQ:CNTX) Issues Quarterly Earnings Results

Context Therapeutics (NASDAQ:CNTX) released its earnings results on Wednesday. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.11), Zacks reports.

Context Therapeutics Stock Down 6.7 %

NASDAQ CNTX traded down $0.14 during trading on Friday, reaching $1.95. 339,093 shares of the stock traded hands, compared to its average volume of 309,652. Context Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $2.75. The firm has a market cap of $146.25 million, a price-to-earnings ratio of -2.14 and a beta of 2.25. The stock’s 50-day moving average price is $2.09 and its 200 day moving average price is $2.06.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of Context Therapeutics in a research report on Monday, September 23rd.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.